Diethylstilbestrol, genetics, teratogenesis, and tumor spectrum in humans

Henry T. Lynch, Jack W. Reich

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Diethylstilbestrol (DES) is the first example of transplacental carcinogenesis in humans, as evidenced by an excess of clear cell adenocarcinoma of the vagina and cervix in exposed women. We hypothesize that: 1) in utero DES exposure will be responsible for a broader spectrum of cancer with variable age of onset as a function of latency effects in exposed humans of both sexes; 2) teratogenicity of DES will be more far-reaching than currently recognized and will harbor cancer implications in the face of known associations between teratogenesis and carcinogenesis; and 3) genetic heterogeneity will be a critical etiologic discriminant in DES associated cancer. This hypothesis embraces a prodigious body of data at the infrahuman level, as well as extant pharmacogenetic and ecogenetic observations in humans which signify heritable variations in response to environmental carcinogenic exposures. This hypothesis has important implications for drug testing with appropriate preventive strategies. Herein, particular restraints with monitoring through governmental legal channels must be employed. Past experience has clearly indicated negligence in shouldering this responsibility by both the pharmaceutical industry and government regulatory bodies.

Original languageEnglish
Pages (from-to)315-332
Number of pages18
JournalMedical Hypotheses
Volume16
Issue number3
DOIs
StatePublished - 1985

Fingerprint

Teratogenesis
Diethylstilbestrol
Neoplasms
Carcinogenesis
Clear Cell Adenocarcinoma
Genetic Heterogeneity
Pharmacogenetics
Malpractice
Environmental Exposure
Drug Industry
Vagina
Age of Onset
Cervix Uteri
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Developmental Biology
  • Medicine(all)
  • Drug Discovery

Cite this

Diethylstilbestrol, genetics, teratogenesis, and tumor spectrum in humans. / Lynch, Henry T.; Reich, Jack W.

In: Medical Hypotheses, Vol. 16, No. 3, 1985, p. 315-332.

Research output: Contribution to journalArticle

@article{2dd8c6cbfa2a4289a06ae3335cc23fe8,
title = "Diethylstilbestrol, genetics, teratogenesis, and tumor spectrum in humans",
abstract = "Diethylstilbestrol (DES) is the first example of transplacental carcinogenesis in humans, as evidenced by an excess of clear cell adenocarcinoma of the vagina and cervix in exposed women. We hypothesize that: 1) in utero DES exposure will be responsible for a broader spectrum of cancer with variable age of onset as a function of latency effects in exposed humans of both sexes; 2) teratogenicity of DES will be more far-reaching than currently recognized and will harbor cancer implications in the face of known associations between teratogenesis and carcinogenesis; and 3) genetic heterogeneity will be a critical etiologic discriminant in DES associated cancer. This hypothesis embraces a prodigious body of data at the infrahuman level, as well as extant pharmacogenetic and ecogenetic observations in humans which signify heritable variations in response to environmental carcinogenic exposures. This hypothesis has important implications for drug testing with appropriate preventive strategies. Herein, particular restraints with monitoring through governmental legal channels must be employed. Past experience has clearly indicated negligence in shouldering this responsibility by both the pharmaceutical industry and government regulatory bodies.",
author = "Lynch, {Henry T.} and Reich, {Jack W.}",
year = "1985",
doi = "10.1016/0306-9877(85)90014-3",
language = "English",
volume = "16",
pages = "315--332",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Diethylstilbestrol, genetics, teratogenesis, and tumor spectrum in humans

AU - Lynch, Henry T.

AU - Reich, Jack W.

PY - 1985

Y1 - 1985

N2 - Diethylstilbestrol (DES) is the first example of transplacental carcinogenesis in humans, as evidenced by an excess of clear cell adenocarcinoma of the vagina and cervix in exposed women. We hypothesize that: 1) in utero DES exposure will be responsible for a broader spectrum of cancer with variable age of onset as a function of latency effects in exposed humans of both sexes; 2) teratogenicity of DES will be more far-reaching than currently recognized and will harbor cancer implications in the face of known associations between teratogenesis and carcinogenesis; and 3) genetic heterogeneity will be a critical etiologic discriminant in DES associated cancer. This hypothesis embraces a prodigious body of data at the infrahuman level, as well as extant pharmacogenetic and ecogenetic observations in humans which signify heritable variations in response to environmental carcinogenic exposures. This hypothesis has important implications for drug testing with appropriate preventive strategies. Herein, particular restraints with monitoring through governmental legal channels must be employed. Past experience has clearly indicated negligence in shouldering this responsibility by both the pharmaceutical industry and government regulatory bodies.

AB - Diethylstilbestrol (DES) is the first example of transplacental carcinogenesis in humans, as evidenced by an excess of clear cell adenocarcinoma of the vagina and cervix in exposed women. We hypothesize that: 1) in utero DES exposure will be responsible for a broader spectrum of cancer with variable age of onset as a function of latency effects in exposed humans of both sexes; 2) teratogenicity of DES will be more far-reaching than currently recognized and will harbor cancer implications in the face of known associations between teratogenesis and carcinogenesis; and 3) genetic heterogeneity will be a critical etiologic discriminant in DES associated cancer. This hypothesis embraces a prodigious body of data at the infrahuman level, as well as extant pharmacogenetic and ecogenetic observations in humans which signify heritable variations in response to environmental carcinogenic exposures. This hypothesis has important implications for drug testing with appropriate preventive strategies. Herein, particular restraints with monitoring through governmental legal channels must be employed. Past experience has clearly indicated negligence in shouldering this responsibility by both the pharmaceutical industry and government regulatory bodies.

UR - http://www.scopus.com/inward/record.url?scp=0022390094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022390094&partnerID=8YFLogxK

U2 - 10.1016/0306-9877(85)90014-3

DO - 10.1016/0306-9877(85)90014-3

M3 - Article

VL - 16

SP - 315

EP - 332

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 3

ER -